LAS VEGAS and RENO, Nev., Oct. 2, 2024 /PRNewswire/ -- Ambetter from SilverSummit Healthplan, a product offered by a Centene Corporation (NYSE: CNC) company. which provides insurance to under-insured and uninsured populations through the State Based Exchange, will offer a variety of affordable health insurance plans in Nevada for plan year 2025. Open enrollment for the Health Insurance Marketplace® for Nevada runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15, 2024, for coverage starting Jan. 1, 2025.
"Nevadans can count on Ambetter from SilverSummit Healthplan. As the only health plan offered in all 17 Nevada counties since 2017, Ambetter's large provider network offers access to primary care and specialists to support your healthcare needs, wherever you may live in our great state," said SilverSummit Healthplan President and Chief Executive Officer Eric Schmacker.
Ambetter from SilverSummit Healthplan offers its members access to quality care, convenient services and valuable rewards. 2025 benefits and offerings include:
Nevada residents interested in learning more about Ambetter from SilverSummit Healthplan or enrolling in a health plan during the open enrollment period may visit Ambetter.SilverSummitHealthplan.com.
About Ambetter from SilverSummit Healthplan
Ambetter from SilverSummit Healthplan serves under-insured and uninsured populations through the Nevada State Based Exchange, Nevada Health Link. Ambetter from SilverSummit Healthplan is underwritten by SilverSummit Healthplan, Inc., which is a Qualified Health Plan issuer in Nevada. For more information, visit ambetterhealth.com/en/nv. This is a solicitation for insurance. For information on your right to receive an Ambetter from SilverSummit Healthplan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/ and scroll to the bottom of the page.
Last Trade: | US$63.63 |
Daily Change: | 1.85 2.99 |
Daily Volume: | 2,885,495 |
Market Cap: | US$33.470B |
October 30, 2024 October 25, 2024 September 11, 2024 August 29, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB